Related Experiment Video
Updated: Jul 10, 2026
09:04
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats
R N Fedorak1, L R Empey, K Walker
1Department of Medicine, University of Alberta, Edmonton, Canada.
Gastroenterology
|April 1, 1992
Summary
Calcium channel blockers like verapamil may treat inflammatory bowel disease by reducing inflammatory leukotrienes and increasing protective prostaglandins, aiding mucosal healing.
Area of Science:
- Gastroenterology
- Pharmacology
- Inflammation Research
Background:
- Prostaglandins protect the gut lining in inflammatory bowel disease (IBD), while leukotrienes promote inflammation.
- Leukotriene synthesis and action are calcium-dependent, unlike prostaglandin pathways.
Purpose of the Study:
- To investigate if calcium channel blockade alters eicosanoid synthesis and promotes healing in IBD models.
- To assess verapamil's effects on mucosal injury, inflammation, and fluid absorption in colitis.
Main Methods:
- Acetic acid-induced colitis model in animals.
- Treatment with verapamil and/or misoprostol.
- Measurement of colonic injury, myeloperoxidase activity, fluid absorption, prostaglandin E2, and leukotriene B4 (LTB4) via rectal dialysis.
Main Results:
- Verapamil significantly improved fluid absorption and reduced ulceration in colitic animals.
- Verapamil decreased LTB4 synthesis by twofold in colitic animals.
- In non-colitic animals, verapamil reduced LTB4 and increased prostaglandin E2 synthesis.
Conclusions:
- Verapamil demonstrates mucosal protection in IBD models by reducing leukotrienes and increasing prostaglandins.
- Differential regulation of arachidonic acid metabolism by calcium channel blockers offers therapeutic potential for IBD.
More Related Videos
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...